Drugs / autologous bone marrow-derived CD133(+) cell
autologous bone marrow-derived CD133(+) cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01404663 | Oct 2011 → Apr 2012 | cerebral palsy | Royan Institute | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous bone marrow-derived CD133(+) cell | “This study was initiated to evaluate the safety of autologous bone marrow-derived CD133(+) cell intrathecal injection.” PMID 25593079 ↗ Nov 2014 |
| Known as | CD133 stem cell injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01404663 ↗ |
| Known as | CD133-positive enriched bone marrow progenitor cells | “Intrathecal injection of CD133-positive enriched bone marrow progenitor cells in children with cerebral palsy: feasibility and safety.” PMID 25593079 ↗ Nov 2014 |
| Modality | Cell therapy | “CD133(+) cells were enriched from the BM samples and intrathecally injected.” PMID 25593079 ↗ Nov 2014 |
| Route | Intrathecal | “intrathecally injected” PMID 25593079 ↗ Nov 2014 |